Trial Profile
A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD").
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2014
Price :
$35
*
At a glance
- Drugs PF 4523655 (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Quark Pharmaceuticals
- 23 Dec 2014 New trial record
- 23 Dec 2014 New trial record